vs
ASP Isotopes Inc.（ASPI）与Cellectis S.A.（CLLS）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是Cellectis S.A.的1.8倍（$16.7M vs $9.5M），ASP Isotopes Inc.同比增速更快（1295.7% vs 375.0%），Cellectis S.A.自由现金流更多（$27.6M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
ASPI vs CLLS — 直观对比
营收规模更大
ASPI
是对方的1.8倍
$9.5M
营收增速更快
ASPI
高出920.7%
375.0%
自由现金流更多
CLLS
多$75.0M
$-47.4M
损益表 — Q4 FY2025 vs Q2 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $9.5M |
| 净利润 | — | $-25.3M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -181.1% |
| 净利率 | — | -265.9% |
| 营收同比 | 1295.7% | 375.0% |
| 净利润同比 | -586.8% | -51.9% |
| 每股收益（稀释后） | — | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPICLLS
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q2 24 | — | $9.5M | ||
| Q3 23 | — | $1.6M | ||
| Q2 23 | — | $2.0M | ||
| Q2 22 | — | $2.7M |
净利润ASPICLLS
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | — | ||
| Q2 24 | — | $-25.3M | ||
| Q3 23 | — | $-17.5M | ||
| Q2 23 | — | $-16.6M | ||
| Q2 22 | — | $-19.5M |
毛利率ASPICLLS
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 97.3% | ||
| Q2 22 | — | 87.9% |
营业利润率ASPICLLS
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | — | ||
| Q2 24 | — | -181.1% | ||
| Q3 23 | — | -1258.1% | ||
| Q2 23 | — | -1180.5% | ||
| Q2 22 | — | -1003.0% |
净利率ASPICLLS
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | — | ||
| Q2 24 | — | -265.9% | ||
| Q3 23 | — | -1064.1% | ||
| Q2 23 | — | -831.6% | ||
| Q2 22 | — | -714.4% |
每股收益（稀释后）ASPICLLS
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | — | ||
| Q2 24 | — | $-0.28 | ||
| Q3 23 | — | $-0.31 | ||
| Q2 23 | — | $-0.20 | ||
| Q2 22 | — | $-0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $149.0M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $148.6M |
| 总资产 | $498.0M | $407.1M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPICLLS
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | — | ||
| Q2 24 | — | $149.0M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $84.4M | ||
| Q2 22 | — | $129.4M |
总债务ASPICLLS
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
股东权益ASPICLLS
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | — | ||
| Q2 24 | — | $148.6M | ||
| Q3 23 | — | $76.1M | ||
| Q2 23 | — | $96.6M | ||
| Q2 22 | — | $180.5M |
总资产ASPICLLS
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | — | ||
| Q2 24 | — | $407.1M | ||
| Q3 23 | — | $209.7M | ||
| Q2 23 | — | $227.7M | ||
| Q2 22 | — | $320.9M |
负债/权益比ASPICLLS
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $28.9M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $27.6M |
| 自由现金流率自由现金流/营收 | -284.7% | 290.5% |
| 资本支出强度资本支出/营收 | 57.9% | 13.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPICLLS
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 24 | — | $28.9M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.4M | ||
| Q2 22 | — | $-60.2M |
自由现金流ASPICLLS
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 24 | — | $27.6M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.9M | ||
| Q2 22 | — | $-61.7M |
自由现金流率ASPICLLS
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 24 | — | 290.5% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -2391.4% | ||
| Q2 22 | — | -2266.7% |
资本支出强度ASPICLLS
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 24 | — | 13.2% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 24.1% | ||
| Q2 22 | — | 56.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
